PADI4 and breast carcinoma: Our finding that the PAD inhibitor, BB-Cl-Amidine, suppresses EGF-induced tumor cell migration, raises the possibility that PAD inhibitors could function in therapeutic formulations for treating EGFR-overexpressing breast cancers.